GlassScriptPhysician profile
Evan Noah Feldman
NPI 1750530630
$6,624.36
in general payments reported to CMS, 2019-2025
35 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,270 · 2020: $1,438 · 2021: $898 · 2022: $613 · 2023: $443 · 2024: $540 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,836.36 | 2019-2021 | |
| Medtronic, INC. | $961.59 | 2021-2025 | Interstim, Gia |
| Musculoskeletal Transplant Foundation INC. | $934.64 | 2020 | |
| Stryker Corporation | $630.25 | 2019-2022 | |
| Davol INC. | $290.07 | 2021-2025 | Surgiphor, Phasix Mesh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.61 | 2022-2024 | Xifaxan, Trulance, Plenvu |
| La Jolla Pharmaceutical Company | $157.40 | 2021-2024 | Xerava |
| Applied Medical Resources Corporation | $153.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.86 | 2020-2025 | Gattex |
| Ferring Pharmaceuticals INC. | $129.67 | 2019-2025 | Rebyota |
| Conmed Corporation | $111.11 | 2020 | |
| Axonics, INC. | $95.67 | 2020-2024 | Axonics |
| Covidien LP | $86.30 | 2019-2020 | |
| Baxter Healthcare | $69.90 | 2021-2025 | Perclot, Tisseel |
| Thd America, INC. | $66.07 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $62.45 | 2020-2025 | Echelon Circular, Enseal X1, Harmonic |
| Lexington Medical, INC. | $59.92 | 2023 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Braintree Laboratories, INC. | $55.12 | 2021-2023 | Suflave |
| Smith+Nephew, INC. | $41.07 | 2025 | Grafix, Stravix |
| Shire North American Group INC | $40.68 | 2019 | |
| Boston Scientific Corporation | $39.45 | 2019 | |
| Merck Sharp & Dohme LLC | $39.35 | 2019-2020 | |
| Heron Therapeutics, INC. | $37.02 | 2022-2023 | Zynrelef |
| Mimedx Group, INC. | $36.27 | 2024 | |
| Kci USA, INC. | $35.79 | 2023 | V.A.C. Veraflo, Prevena |
| Micro-Tech Endoscopy USA, INC. | $31.34 | 2021 | |
| Convatec INC. | $30.12 | 2019-2021 | |
| Integra Lifesciences Corporation | $27.32 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $25.78 | 2024 | Exparel |
| Innovation Technologies INC | $25.17 | 2025 | Irrisept |
| Trevena, INC. | $24.96 | 2022 | |
| Solventum Corporation | $20.05 | 2025 | Prevena |
| Allergan, INC. | $17.53 | 2019 | |
| Prescient Surgical | $13.64 | 2019 | |
| Zyla Life Sciences, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.